Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
108.56
-1.14 (-1.04%)
Oct 3, 2024, 4:00 PM EDT - Market closed
Jazz Pharmaceuticals Revenue
Jazz Pharmaceuticals had revenue of $1.02B in the quarter ending June 30, 2024, with 6.95% growth. This brings the company's revenue in the last twelve months to $3.91B, up 3.91% year-over-year. In the year 2023, Jazz Pharmaceuticals had annual revenue of $3.83B with 4.78% growth.
Revenue (ttm)
$3.91B
Revenue Growth
+3.91%
P/S Ratio
1.74
Revenue / Employee
$1,396,387
Employees
2,800
Market Cap
6.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
| Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
| Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
| Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
| Dec 31, 2019 | 2.16B | 270.84M | 14.32% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.30B |
| Bausch + Lomb | 4.50B |
| PACS Group | 3.56B |
| R1 RCM | 2.38B |
| HealthEquity | 1.10B |
| Ionis Pharmaceuticals | 813.46M |
| Inspire Medical Systems | 705.71M |
| Glaukos | 341.73M |
JAZZ News
- 17 days ago - Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024 - PRNewsWire
- 24 days ago - Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024 - PRNewsWire
- 4 weeks ago - Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024 - PRNewsWire
- 4 weeks ago - Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases - PRNewsWire
- 4 weeks ago - Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases - PRNewsWire
- 6 weeks ago - Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies - PRNewsWire
- 6 weeks ago - Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences - PRNewsWire
- 2 months ago - Jazz Pharmaceuticals plc (JAZZ) Q2 2024 Earnings Call Transcript - Seeking Alpha